Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2025
Filed with the SEC on Feb 3, 2026 and accepted by EDGAR at Feb 3, 2026, 08:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-10-01 to 2025-12-31 | $65.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-04-01 to 2025-12-31 | $185.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-10-01 to 2025-12-31 | $23.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2025-04-01 to 2025-12-31 | $69.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-10-01 to 2025-12-31 | $41.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-04-01 to 2025-12-31 | $116.1m | us-gaap:GrossProfit |
| Research and development | 3 months2025-10-01 to 2025-12-31 | $5.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-04-01 to 2025-12-31 | $15.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-10-01 to 2025-12-31 | $8.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-04-01 to 2025-12-31 | $15.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-10-01 to 2025-12-31 | $3.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2025-04-01 to 2025-12-31 | $8.1m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-10-01 to 2025-12-31 | $966.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-04-01 to 2025-12-31 | $2.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-10-01 to 2025-12-31 | $3.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-04-01 to 2025-12-31 | $10.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-10-01 to 2025-12-31 | $0.65 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-04-01 to 2025-12-31 | $1.95 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-10-01 to 2025-12-31 | $0.66 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-04-01 to 2025-12-31 | $1.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-10-01 to 2025-12-31 | 5,565,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-04-01 to 2025-12-31 | 5,552,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-04-01 to 2025-12-31 | $28.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-04-01 to 2025-12-31 | $2.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2025-04-01 to 2025-12-31 | $2.6m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2025-12-31 | $29.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $105.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $434.8m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $54.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $248.2m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $68.4m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2025-12-31 | $186.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000724004-26-000016. Last ingested by Listed: Oct 29, 2026, 18:36 ET. Listed shows no prices and gives no investment advice.